Join BiomX for a virtual key opinion leader (KOL) event featuring Dr. Robert T. “Chip” Schooley, MD (University of California, San Diego) and Dr. Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP (University of Washington, Seattle), who will join BiomX senior management to discuss topline positive safety and efficacy results from the Company’s DANCE™ Phase 2 trial evaluating its BX211 phage treatment for DFO associated with Staphylococcus aureus (S. aureus).

BX211 is a phage treatment for the treatment of DFO associated with S. aureus. DFO is a bacterial infection of the bone that usually develops from an infected foot ulcer and is a leading cause of amputation in patients with diabetes. BiomX is currently preparing plans for future clinical development of BX211.

A live question and answer session will follow the formal presentations.